title: Identification of microRNA-205 as a potential prognostic indicator for human glioma.
abstract: Altered microRNA-205 (miR-205) expression has been found in glioma tissue samples and cell lines; however, the clinical significance of this is unclear. The aim of this study was to confirm the miR-205 expression pattern in human glioma and to investigate its clinical relevance. Quantitative reverse-transcription polymerase chain reaction assays showed that miR-205 expression was significantly lower in glioma tissues than in non-neoplastic brain tissues (P<0.001). Statistical analysis revealed a significant correlation between low miR-205 expression and both high grade glioma (World Health Organization [WHO] criteria, P=0.008) and a low Karnofsky performance status score (P=0.02). Survival analysis demonstrated that the cumulative 5-year overall survival rate of patients with glioma in the high miR-205 expression group was significantly higher than that in the low miR-205 expression group (P<0.001). Multivariate Cox regression analysis further indicated that miR-205 expression (P=0.01) and WHO grade (P=0.01) were independent prognostic indicators of the overall survival of patients with glioma. Moreover, subgroup analyses revealed that the cumulative 5-year overall survival rate of patients with high grade (III-IV) glioma was significantly worse for the low miR-205 expression group than for the high miR-205 expression group (P<0.001), but no significant difference was found for patients with low grade (I-II) glioma (P=0.09). In conclusion, down-regulation of miR-205 was associated with glioma progression. Our data are the first to suggest that miR-205 holds potential as a prognostic factor for glioma, especially for patients with advanced disease.
authors.affiliation: Department of Neurology, Xi-jing Hospital, Fourth Military Medical University, 127 West Chang Le Road, Xi'an 710032, China.
authors.forename: Shuang-xing
authors.initials: SX
authors.lastname: Hou
authors.forename: Bo-jun
authors.initials: BJ
authors.lastname: Ding
authors.forename: Hong-zeng
authors.initials: HZ
authors.lastname: Li
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Xia
authors.forename: Fang
authors.initials: F
authors.lastname: Du
authors.forename: Li-juan
authors.initials: LJ
authors.lastname: Liu
authors.forename: Yong-hong
authors.initials: YH
authors.lastname: Liu
authors.forename: Xue-dong
authors.initials: XD
authors.lastname: Liu
authors.forename: Jun-feng
authors.initials: JF
authors.lastname: Jia
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Zhong-liang
authors.initials: ZL
authors.lastname: Wu
authors.forename: Gang
authors.initials: G
authors.lastname: Zhao
authors.forename: Zhi-guo
authors.initials: ZG
authors.lastname: Zhang
authors.forename: Yan-chun
authors.initials: YC
authors.lastname: Deng
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D015536:Down-Regulation; D005260:Female; D005910:Glioma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008297:Male; D035683:MicroRNAs / Q000032:analysis* / Q000096:biosynthesis; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D020133:Reverse Transcriptase Polymerase Chain Reaction; D059467:Transcriptome
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; C534425:MIR205, human